Linaprazan

Linaprazan
Clinical data
Other names	AZD-0865
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 8-[(2,6-Dimethylphenyl)methylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide;
CAS Number	248919-64-4;
PubChem CID	9951066;
UNII	E0OU4SC8DP;
Chemical and physical data
Formula	C21H26N4O2
Molar mass	366.465 g·mol−1

Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB).^[1]^[2] Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.^[3]

The drug was then licensed to Cinclus Pharma,^[4] which is now investigating linaprazan glurate, a prodrug of linaprazan which is expected to have a longer biological half-life than linaprazan itself.^[4]

References

[1]

[2]

[3]

[4]